Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer.
Autoimmune phenomena are frequently associated with differentiated thyroid carcinomas. However, the significance of thyroid gland autoimmune aggression on the outcome of these patients is still controversial. To address this issue, we studied 173 patients (123 with papillary and 50 with follicular carcinomas) who underwent surgery complemented by radioiodine ablation and followed up for 0.5-29 (6 +/- 5.76) years. Analysis of the prognostic factors revealed that higher age, male gender, larger nodule size, follicular tumors, presence of metastases at diagnosis, grade of differentiation, and stage correlated positively with the occurrence of death, metastasis and/or recurrence, while the presence of antibodies and the previous history of autoimmune disease correlated negatively with these events. Long distant metastases increased the odds for a lower disease-free rate for patients with papillary (8.366 times) and follicular (7.373 times) carcinoma. However, univariate and multivariate analysis failed to demonstrate that neck node involvement could influence the outcome for patients with well-differentiated thyroid carcinoma. The odds for patients with previous history of thyroid autoimmune disease (p < 0.02) or with thyroid autoantibodies (p < 0.001) to have a worse outcome were lower than for patients with no evidence of autoimmune activity, suggesting that autoimmune activity against the gland may exert a protective effect on the outcome of differentiated thyroid carcinoma patients.
Souza
Suzikelli Lisboa
SL
Laboratory of Cancer Molecular Genetics, Department of Medicine, State University of Campinas, São Paulo, Brazil.
Montalli Da Assumpção
Lígia Vera
LV
Ward
Laura Sterian
LS
D018263:Adenocarcinoma, Follicular / Q000276:immunology / Q000473:pathology / Q000628:therapy; D000328:Adult; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000150:complications / Q000276:immunology*; D002291:Carcinoma, Papillary / Q000276:immunology / Q000473:pathology / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013959:Thyroid Diseases / Q000150:complications / Q000276:immunology*; D013961:Thyroid Gland / Q000276:immunology; D013964:Thyroid Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
D001323:Autoantibodies